Study of Pre-identified methylation marker gene as a gastric cancer biomarker
Not Applicable
Recruiting
- Conditions
- Health Condition 1: C169- Malignant neoplasm of stomach, unspecified
- Registration Number
- CTRI/2024/01/061396
- Lead Sponsor
- orth Eastern Hill University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Gastric cancer patients attending the surgical oncology OPD.
2.Patients who are willing to participate.
3.Age = 18.
Exclusion Criteria
1.History of combination of other types of cancer.
2.Non-availability of matched cancer and normal tissue from the same patient.
3.Non-availability of patient data.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Degree of methylation of the proposed genes. <br/ ><br>2. Expressional difference of the proposed genes.Timepoint: 1.1st week of participation:Gene expression analysis. <br/ ><br>2.2nd week of participation: Gene methylation analysis.
- Secondary Outcome Measures
Name Time Method Association between the specific gene methylation with TNM status, Personal habits.Timepoint: 3rd week of participation.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the pre-identified methylation markers in gastric cancer progression?
How do pre-identified methylation marker genes compare to traditional biomarkers like HER2 in gastric cancer patient selection?
What are the potential adverse events associated with methylation-based biomarkers in gastric cancer diagnostics?
Are there combination therapies involving methylation markers and standard-of-care drugs for C169 stomach malignancies?
What is the current landscape of gastric cancer biomarkers, and how might this trial's findings impact patient stratification strategies?